Management of Ventricular Tachycardia in the Setting of a Dedicated Unit for the Treatment of Complex Ventricular Arrhythmias: Long-Term Outcome After Ablation
Catheter ablation plays a relevant role in the treatment of drug-refractory ventricular tachycardia (VT) episodes, recurrent implantable cardioverter-defibrillator shocks, lowering VT recurrence and improving quality of life. Data about the effects of catheter ablation on survival are still controversial. We implemented a multidisciplinary model, aiming for multiskilled management of this critical population from patients' admittance to electrophysiological procedure, therapy optimization, and close follow-up. We provide the largest clinical experience to date investigating the potential benefit of catheter ablation for the treatment of VT in patients with any type of structural heart disease. Risk stratification on admission was the first step of our approach to VT management, and it allowed the identification of patients at high risk of developing an adverse outcome, who were treated subsequently by a comprehensive and multidisciplinary approach. Five hundred twenty-eight patients were treated by ablation; after a median follow-up of 26 months, VT recurrence rate and cardiac mortality were significantly lower in patients without any VT inducibility at programmed stimulation after the procedure than in those with induction of nonclinical VT and those with persistence of clinical VT inducibility. On the basis of multivariate analysis, postprocedural inducibility of index VT was independently associated with both VT recurrence and cardiac mortality. Catheter ablation favorably affects VT recurrence, hospitalization, and survival in a large cohort of patients with VT; therefore, it might be proposed as elective treatment for VT even in patients with advanced heart disease and severe comorbidities. See p 1359.
Status of Cardiovascular Health in US Adolescents: Prevalence Estimates From the National Health and Nutrition Examination Surveys (NHANES) 2005-2010
The American Heart Association has committed to the goal of making a 20% improvement in the cardiovascular health of all Americans-both children and adults-by the year 2020. In the present article, we estimate the current status of cardiovascular health among US adolescents aged 12 to 19 years according to sex and race/ethnicity groups. These data highlight the unacceptably high prevalence of cardiovascular health behaviors (eg, poor diet, insufficient physical activity, smoking exposure) and environmental factors (eg, excess sodium intake) that adversely influence cardiovascular health in US adolescents. Atherosclerosis begins in childhood and progresses to advanced calcified coronary plaque in the early decades of adulthood. Therefore, postponement of intervention until presentation of elevated risk factors in middle age actually results in secondary prevention because advanced disease is already present. The unfavorable levels of cardiovascular health components currently present in youth populations strongly emphasize the need for public health policy initiatives focusing on improving the current cardiovascular health of Americans starting in childhood. Individual-level interventions are often ineffective as a result of limited physician effort, limited preventive care reimbursement, and unsupportive environmental factors. Consequently, broad social and cultural changes that infiltrate the entire population are necessary to evoke changes in youth behaviors that will favorably influence cardiovascular health. The comprehensive support of parents, healthcare professionals, educators, scientists, and legislators is required to ignite a social movement influential enough to facilitate the change needed to improve the currently worrisome status of cardiovascular health in youth populations and to prevent an increased incidence of premature coronary heart disease as the current US youth reach adulthood. See p 1369.
Genome-and Phenome-Wide Analyses of Cardiac Conduction Identifies Markers of Arrhythmia Risk
QRS duration, a measure of cardiac intraventricular conduction, varies ≈2-fold in individuals without cardiac disease. Slow conduction may promote re-entrant arrhythmias. We identified 5272 individuals with normal ECGs and no evidence of cardiac disease from electronic medical records at 5 institutions and performed genome-wide association analysis. We found variants in 5 loci associated with QRS duration in normal individuals, including SCN5A, SCN10A, NFIA, near CDKN1A, and near SLC35F1, that were replicated in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium QRS meta-analysis. Subsequently, we performed phenome-wide association studies on associated single-nucleotide polymorphisms. These analyses demonstrated with SCN5A-10A variants were associated with the future development of atrial fibrillation and cardiac arrhythmias. We conclude that DNA biobanks coupled to electronic medical records provide a platform not only for genome-wide association studies but also for broadly interrogating the longitudinal incidence of disease associated with genetic variants. See p 1377.
Association Between Physician Follow-Up and Outcomes of Care After Chest Pain Assessment in High-Risk Patients
Chest pain is one of the most common reasons for visiting the emergency department in developed countries. However, little is known about the impact of physician follow-up and specialist care on outcomes after discharge from the emergency department. We evaluated the patterns of care and outcomes of chest pain patients at higher baseline cardiovascular risk after emergency department discharge in Ontario, Canada. Among 56 767 patients with diabetes mellitus or preexisting cardiovascular disease, 25% had no physician follow-up, 58% were evaluated by primary care physicians, and 17% were evaluated by cardiologists within 30 days of emergency department assessment. At 1 year, patients cared Volume 127 ◼ Number 13 ◼ April 2, 2013
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April 2, 2013 for by cardiologists had the lowest rate of death or myocardial infarction at 5.5%, followed by patients cared for by primary care physicians at 7.7%; patients who had no physician follow-up had the highest event rate at 8.6%. These differences remained significant after adjustment for clinical characteristics between physician groups. Our study demonstrated a significant gap in the transition of care for chest pain patients after discharge from the emergency department and emphasized the need to provide physician follow-up for higher-risk patients. See p 1386.
Effect of Race and Ethnicity on Outcomes With Drug-Eluting and Bare Metal Stents: Results in 423 965 Patients in the Linked National Cardiovascular Data Registry and Centers for Medicare & Medicaid Services Payer Databases
Randomized trials have found that drug-eluting stent use for the treatment of obstructive coronary artery disease reduces repeat revascularization rates with similar survival and myocardial infarction rates compared with bare metal stents. However, these studies were predominantly performed in white patients, so limited data exist on outcomes for black, Hispanic, and Asian patients. We used the National Cardiovascular Data Registry CathPCI Registry linked to Medicare claims to examine outcomes for these understudied racial/ ethnic groups. We included all CathPCI Registry patients ≥65 years of age undergoing a coronary stent procedure between January 1, 2004, and December 31, 2008. Relative to white patients, we found that black and Hispanic patients have a significantly greater risk of adverse cardiac events after percutaneous coronary intervention, although long-term outcomes between Asians and whites are similar. We also found better performance of drug-eluting stents compared with bare metal stents in all groups except Hispanics, in whom drug-eluting stent and bare metal stent performance was similar. To the best of our knowledge, this is one of the first studies to examine percutaneous coronary intervention outcomes for a large cohort of minority patients, to compare these outcomes relative to outcomes in white patients, and specifically to evaluate the performance of drug-eluting and bare metal stents within each group. Our findings are significant to clinical practice by providing clinicians with new information on long-term percutaneous coronary intervention outcomes for specific racial/ ethnic groups, including data evaluating drug-eluting and bare metal stent performance, which may help in risk stratification and treatment selection to optimize clinical outcomes and to improve resource use for black, Hispanic, and Asian patients undergoing percutaneous coronary intervention for the treatment of coronary artery disease. See p 1395.
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding
Dabigatran etexilate is the first new oral anticoagulant approved by the European and North American regulatory authorities for stroke prevention in patients with atrial fibrillation and has been prescribed for hundreds of thousands of patients. Despite the excellent efficacy and safety results reported in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, concerns have emerged about an excess of bleeding complications with dabigatran, particularly in elderly patients and those with moderate renal impairment. Results of our genome-wide association study conducted in 2944 RE-LY trial patients demonstrate that common genetic variants of the esterase gene CES1, involved in dabigatran etexilate metabolism, and the P-glycoprotein efflux transporter ABCA1, involved in dabigatran transport, are associated with lower plasma drug levels and substantially lower risk of bleeding. The magnitude of decreased bleeding risk associated with these genetic variants is even greater than that seen in a comparison of the 2 doses of dabigatran tested in the RE-LY trial, raising the possibility that routine genotyping may enable clinicians to further tailor the dose of dabigatran for individual patients and thereby optimize the balance between efficacy and safety. See p 1404.
